These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. de Sonnaville JJ, Snoek FJ, Colly LP, Devillé W, Wijkel D, Heine RJ. Diabetes Care; 1998 Jun; 21(6):919-24. PubMed ID: 9614608 [Abstract] [Full Text] [Related]
3. Weight gain in type 2 diabetes mellitus. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Diabetes Obes Metab; 2007 May; 9(3):386-93. PubMed ID: 17391167 [Abstract] [Full Text] [Related]
4. Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes: Empowerment Perceptions and Diabetes Distress as Important Determinants. Chen SY, Hsu HC, Wang RH, Lee YJ, Hsieh CH. Biol Res Nurs; 2019 Mar; 21(2):182-189. PubMed ID: 30585081 [Abstract] [Full Text] [Related]
5. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes. Paul SK, Shaw JE, Montvida O, Klein K. Diabetes Obes Metab; 2016 Dec; 18(12):1244-1252. PubMed ID: 27502528 [Abstract] [Full Text] [Related]
6. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). Gao L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Wu Y, Garg SK, Ji L. J Diabetes; 2020 Sep; 12(9):668-676. PubMed ID: 32329194 [Abstract] [Full Text] [Related]
9. Insulin therapy, weight gain and prognosis. Hodish I. Diabetes Obes Metab; 2018 Sep; 20(9):2085-2092. PubMed ID: 29785843 [Abstract] [Full Text] [Related]
10. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. Di Dalmazi G, Coluzzi S, Baldassarre MPA, Sorbo SE, Dell'Aquila S, Febo F, Ginestra F, Graziano G, Rossi MC, Consoli A, Formoso G. Clin Ther; 2020 Sep; 42(9):1738-1749.e1. PubMed ID: 32753164 [Abstract] [Full Text] [Related]
11. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. Kawamori R, Node K, Hanafusa T, Atsumi Y, Naito Y, Oka Y. Cardiovasc Diabetol; 2013 Sep 08; 12():131. PubMed ID: 24011395 [Abstract] [Full Text] [Related]
12. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Clin Ther; 2009 Jul 08; 31(7):1511-23. PubMed ID: 19695400 [Abstract] [Full Text] [Related]
13. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Chow CC, Tsang LW, Sorensen JP, Cockram CS. Diabetes Care; 1995 Mar 08; 18(3):307-14. PubMed ID: 7555472 [Abstract] [Full Text] [Related]
14. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK. Diabetes Care; 1998 Apr 08; 21(4):574-9. PubMed ID: 9571345 [Abstract] [Full Text] [Related]
15. Weight gain in type 2 diabetes mellitus--not all uphill. Cohen O, Norymberg C, Neumann E, Dekel H. Diabetes Res Clin Pract; 2008 Jan 08; 79(1):128-32. PubMed ID: 17720273 [Abstract] [Full Text] [Related]
16. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Strowig SM, Avilés-Santa ML, Raskin P. Diabetes Care; 2004 Jul 08; 27(7):1577-83. PubMed ID: 15220231 [Abstract] [Full Text] [Related]
17. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Hunt B, Mocarski M, Valentine WJ, Langer J. Adv Ther; 2017 Apr 08; 34(4):954-965. PubMed ID: 28281218 [Abstract] [Full Text] [Related]
18. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. van Dieren S, Czernichow S, Chalmers J, Kengne AP, de Galan BE, Poulter N, Woodward M, Beulens JW, Grobbee DE, van der Schouw YT, Zoungas S. Diabetes Obes Metab; 2012 May 08; 14(5):464-9. PubMed ID: 22226008 [Abstract] [Full Text] [Related]
19. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N. Clin Ther; 2007 Nov 08; 29(11):2374-84. PubMed ID: 18158078 [Abstract] [Full Text] [Related]
20. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS. Diabetes Care; 1995 Aug 08; 18(8):1113-23. PubMed ID: 7587846 [Abstract] [Full Text] [Related] Page: [Next] [New Search]